Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Authors:

Abstract
No abstract available
Funding Information
  • Eisai Incorporated

This publication has 31 references indexed in Scilit: